We read the recently published article of the two cases of presumed CMV
induced biliary atresia by Mohanty, et al. [1] and would like to
make some pertinent comments.
The phenomenon of patent biliary tree at birth and
subsequent development of biliary atresia later in the neonatal or
infantile period has never been documented till date. In that sense, the
authors have tried to report this phenomenon for the first time in the
world literature. However, there are several caveats in this hypothesis
proposed by the authors [1]. Firstly, the diagnosis of patent biliary
tree by scintigraphy (case 1) and MRCP (case 2) by authors needs further
clarification. It has been shown by us and many others that short of
per-operative cholangiogram (the gold standard in the diagnosis of BA)
liver biopsy has got the best accuracy in diagnosing biliary atresia
[2,3]. The reported accuracy of scintigraphy in diagnosing biliary
atresia is 77 to 84.5% which improves with 48 to 72 hours of
ursodeoxycholic acid (UDCA) to 91% [4, 5]. Nevertheless, it is nowhere
near 100% and the reported negative predictive value of 76% suggests
that the scintigraphic documentation of excretion does not rule out
biliary atresia [4]. We need to remember before interpreting
scintigraphic report that urinary contamination of the abdomen during
the procedure, inadequate labelling of radioisotope tracer or avid renal
uptake may mimic an excretory HIDA scan. Secondly, documentation of
patent biliary tree by MRCP in an infant is also fallacious. MRCP in an
infant has technical difficulties. Spatial resolution is poor in small
infants, possible movement artefacts and most importantly absent bile
flow in a non-dilated biliary system makes interpretation difficult.
Diagnostic accuracy of MRCP is 71-82% with reports of both false
positive and false negative results [4]. That is why, despite being
non-invasive and available in major hospitals across the globe, it has
not become a popular investigation for BA. Interestingly, within 15 days
of documenting patent biliary tree by MRCP, liver biopsy showed biliary
atresia in the second case. That amply supports our view that the
diagnosis of BA was missed in both the cases in the first instance as
liver biopsy or per-operative cholangiograms were not used in the first
go.
The question of CMV causing or triggering the
development of BA was earlier widely debated but most researchers now
feel that there is no association of the same [5]. It is merely a
confounding factor as up to 24% of BA patients demonstrate serum IgM CMV
positivity. It is mandatory to demonstrate congenital CMV infection of
the liver by inclusion bodies or DNA extraction by hybridisation
techniques from bile ducts, not shown in either of the two cases.
Acquired CMV infection itself is rare (1.1-2.4%) in a neonate for the
first 90 days of life and for this subset to develop BA is next to
impossible [5]. It is well known that rising titres of IgG CMV have a
poor prognostic value, as demonstrated in case 2. Had this been a true
CMV infection leading to BA, there should have been some response to
ganciclovir therapy, which was not there in either of the two reported
cases. There is no recommendation to treat neonatal hepatitis with CMV
(as presumed by the authors) with ganciclovir. Such a message would be
inappropriate.
We feel that both the cases were BA from the very
beginning, the confounding CMV reports and its treatment delayed the
portoeneterostomy. Case 1 had a poor prognosis due to delayed
presentation with decompensated liver disease (ascites and coagulopathy)
and the portoenterostomy was further delayed by 6 weeks due to
ganciclovir trial for CMV. In Case 2, there was a long gap of 3 months
between presentation and surgery due to the confusion of CMV and BA.
In a previous study Tarr, et al. [5] have
doubted the significance of CMV serology in biliary atresia cases. They
voiced their apprehensions of increasingly delayed referral for surgery
if unnecessary treatment for the above was pursued. Both these cases
have shown that mere presence of CMV antibody should not deter the
search for BA.
References
1. Mohanty S, Shah I, Bhatnagar S. Evolving biliary
atresia with cytomegalovirus. Indian Pediatr.2011;48:644-6.
2. Poddar U, Thapa BR, Das A, Bhattacharya A, Rao KL,
Singh K. Neonatal cholestasis: differentiation of biliary atresia from
neonatal hepatitis in a developing country. Acta Paediatr.
2009;98:1260-4.
3. Poddar U, Bhattacharya A, Thapa BR, Mittal BR,
Singh K. Ursodeoxycholic acid-augmented hepatobiliary scinti-graphy in
the evaluation of neonatal jaundice. J Nucl Med. 2004;45:1488-92.
4. Norton KI, Glass RB, Kogan D, Lee JS, Emre S,
Shneider BL. MR cholangiography in the evaluation of neonatal
cholestasis: initial results. Radiology. 2002;222:687-91.
5. Tarr PI, Haas JE, Christie DL. Biliary atresia, cytomegalovirus,
and age at referral. Pediatrics. 1996; 97:828-31.